Verteporfin

製品コードS1786 別名:CL 318952

Verteporfin 化学構造

分子量(MW):718.79

Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.

サイズ 価格(税別)  
JPY 55100
JPY 163000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

VDA阻害剤の選択性比較

生物活性

製品説明 Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.
ターゲット
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
体外試験

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 Moj1SpVv[3Srb36gZZN{[Xl? NVHOZoNYhjFyMDDu[{9uVA>? NHz2fINFVVOR MWrpcoNz\WG|ZYOgSG5CKG[{YXft[Y51[XSrb36gcIV3\Wy| M1HnbVExPjB5N{Gw
HL-60 MVrjfZRwfG:6aXPpeJkh[XO|YYm= MVf+NVAxKG6pL33M NF7Sbo9FVVOR Mmq2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M2PaW|ExPjB5N{Gw
Jurkat MoPRRZBweHSxc3nzJIF{e2G7 MoHnglI5OCCwTR?= M{fmemROW09? MmDpbY5lfWOnczDhJGJkdC1{LXTldIVv\GWwdDDhdI9xfG:|aYO= M3jnZlEyOjR3NEG1
RIF-1 NYH6TZhKTnWwY4Tpc44h[XO|YYm= NVrZWIV[OSEQvHevcYw> NUnyPYpITE2VTx?= M360SYRm[3KnYYPld{BwgHmpZX6gZ49ve3WvcITpc44> NF\J[XIyOjZzNUexPC=>
RIF-1 NXW0bnFS[3m2b4TvfIlkcXS7IHHzd4F6 NVjzc4w2OSEQvHevcYw> M{XhSGROW09? NHjGbpNl\WO{ZXHz[UB1dyB{MDFCtUA2LSClZXzsJJN2en[rdnHs NYHxe|lKOTJ4MUW3NVg>
SVEC4-10 NX[2cHZGTnWwY4Tpc44h[XO|YYm= M1n1OFIxOCCwZz;tcC=> NYDVdWdpTE2VTx?= NG\Z[lVqdmS3Y3XzJI1q[3KxdIXieYxmKGSncH;sfY1memm8YYTpc44> MonKNVY1PjdzME[=
SVEC4-10 MXTGeY5kfGmxbjDhd5NigQ>? NWXVS|VjOjByIH7nM41t NHzRSGFFVVOR MmH1bY5lfWOnczDzeJJme3NiYXP0bY4h\mmkZYKg[o9zdWG2aX;u M3PNVFE3PDZ5MUC2
ARPE-19 MmrBZ5l1d3SxeHnjbZR6KGG|c3H5 MWT+NE4yKM7:Zz;tcC=> NHvMcJRFVVOR MnPSd4hwf3NiYTDkc5NmNWSncHXu[IVvfCC2b4jpZ4l1gQ>? M2DQVlE3QTh5OUC1
ARPE-19 MlPWSpVv[3Srb36gZZN{[Xl? MmnkNE4xOSEQvHevcYw> MmrTSG1UVw>? M2Wyfolv[3KnYYPld{BXTUeIIHHu[EBz\WS3Y3XzJHBGTEZiZYjwdoV{e2mxbh?= NUjrdG86OTZ7OEe5NFU>
Y-79 MomxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUP+NUDPxGdxbXy= NX;kd3EyTE2VTx?= Mofr[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= MXWxPFU4QTd4NB?=
WERI-Rb1 M1fxTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mm\MglEh|rypL33s NVLYVpFiTE2VTx?= MYHk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w MlX4NVg2Pzl5NkS=
RB247C3 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYP+NUDPxGdxbXy= MoTXSG1UVw>? NUj5ZZNN\GWlcnXhd4V{KHKndHnuc4Jt[XO2b33hJINmdGxicILvcIln\XKjdHnvci=> MX:xPFU4QTd4NB?=
RB355 M{iyV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4TEd54yKM7:Zz;tcC=> MW\EUXNQ M3uyT4Rm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= MnvKNVg2Pzl5NkS=
RB383 NXfSTFQzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NX21T3p5hjFizsznM41t NVHJSFFiTE2VTx?= M1niboRm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= NIi3e2kyQDV5OUe2OC=>
hFibro NEHycI5kgXSxdH;4bYNqfHliYYPzZZk> MW[wMlUhyrWpL33s NFfpXIhFVVOR M37kW4Rm[3KnYYPld{B3cWGkaXzpeJkh[nliOE[sOUU> NWKzTHdXOjN2NEGxNVQ>
pTMC M1vGcYN6fG:2b4jpZ4l1gSCjc4PhfS=> NXzSTm54OC53INM1[{9udA>? NX[wNlBiTE2VTx?= MV\k[YNz\WG|ZYOgeoli[mmuaYT5JIJ6KDl{Lkml M4npNlI{PDRzMUG0
hTMC M1PsO4N6fG:2b4jpZ4l1gSCjc4PhfS=> MYmwMlUhyrWpL33s NV62SohuTE2VTx?= NGTaXYZl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEi4Mlkm NWXCOno5OjN2NEGxNVQ>
ARPE-19 NVrZNXE2[3m2b4TvfIlkcXS7IHHzd4F6 NUTpZnV{OC53INM1[{9udA>? MVzEUXNQ NIfDc4dl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEW1MlUm MXuyN|Q1OTFzNB?=
Panc-1 MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXPXcndsOTBizszN NVHwbIV6TE2VTx?= MWjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= NYDoeHNbOjRyNkmwOlk>
MIA PaCa-2 NFTWR2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXLQU3hvOTBizszN NUDpSI9STE2VTx?= M33JUYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> MXqyOFA3QTB4OR?=
BxPC-3 MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NG[weoIyOCEQvF2= Ml\wSG1UVw>? MofZbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJk> NYfOVJQyOjRyNkmwOlk>
SU86.86 M4TaXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmHHNVAh|ryP NVPXVoZPTE2VTx?= Mlv4bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJk> MWSyOFA3QTB4OR?=
MCF-7 NYHwXnFjSXW2b4DoZYd6KGG|c3H5 Mm\qNVAh|ryP MYTEUXNQ M4jvZ4lvcGmkaYTzJIdmdWOrdHHibY5mNWmwZIXj[YQh[XW2b4DoZYd6 NHv1eXQzPDB4OUC2PS=>
WERI M2fkdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1n2Op4yOCEQvHevcYw> M4rte2ROW09? MkXIbY5pcWKrdIOg[5Jwf3SqIH;mJJJmfGmwb3LsZZN1d22jIHPlcIx{ NWnyPHpyOjR6M{exOFI>
WERI M2nnOWZ2dmO2aX;uJIF{e2G7 MlTWglExKM7:Zz;tcC=> M1KwN2ROW09? MV3icI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> NHvZPHMzPDh|N{G0Ni=>
Y-79 NGDlZWhHfW6ldHnvckBie3OjeR?= M4HRWZ4yOCEQvHevcYw> MWDEUXNQ MXLicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> MUGyOFg{PzF2Mh?=
Y-79 M3PQbGZ2dmO2aX;uJIF{e2G7 M4fkdZ4yOCEQvHevcYw> MXLEUXNQ M1HYOIFn\mWldIOgXWFRNVSHQVSgdJJwfG9vb37jc4dmdmVicHH0bJdigQ>? NFHOWYgzPDh|N{G0Ni=>
Y-79 NELRWI1HfW6ldHnvckBie3OjeR?= MUT+NVAh|rypL33s NGX1PFBFVVOR MXTkc5dvNXKnZ4XsZZRmeyCybIXybZBwfGWwY4mgcYFzc2W{IF;DWE01 NFv1[2IzPDh|N{G0Ni=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-S6(S240/244) / p-4EBP1(S65); 

PubMed: 28202507     


KLE, EFE184 and NOU-1 were treated with Verteporfin (0.1 μM, 0.3 μM). After 36h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

c-Myc / Bcl-2; 

PubMed: 29416644     


In CAL27 cell lines, the expression of BCL-2 and C-MYC proteins decreased with the increase of Verteporfin concentration. The presented columns are given as the means ± SD. *p < 0.05, **P < 0.01, ***p < 0.001.

ECAD / Vimentin / Sox2 / CD44 / CD133; 

PubMed: 30467925     


Yes-associated protein 1 (YAP1), E-cadherin, vimentin (epithelial-mesenchymal transition [EMT] pathway), SOX2 CD44 and CD133 (autophagy markers) were detected by western blot in control, verteporfin (1 μmol/L) and verteporfin + 231-taxol (0.5 μmol/L) resistance groups.

beta-catenin; 

PubMed: 28202507     


KLE, EFE184, NOU-1 and SKUT-2 were treated with 3 μM Verteporfin. After 24h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

28202507 29416644 30467925
Growth inhibition assay
Cell viability; 

PubMed: 28042502     


A: Cell viability was determined by MTS assay after the UM cells were exposed to verteporfin for 72 hours. B: After treated with various concentrations of verteporfin for 24 hours, the UM cells (e.g., 92.1, Mel 270, Omm 1, Omm 2.3) were seeded in drug-free soft agar culture for 14 days. Colonies were counted. 

28042502
Immunofluorescence
YAP1; 

PubMed: 30254296     


Treatment of U343 cells with 5 μM VP between 1-8 h in both 21% and 1% O2 induced morphological changes. Scale bar represents 10 µm. VP: Verteporfin

Calreticulin; 

PubMed: 30254296     


Calreticulin (CRT) significantly increased in VP-treated (5 µM, 2 h) U87 cells in both 21% and 1% O2 indicating likely ER stress.

p-YAP(Y357); 

PubMed: 28404908     


Confocal images of HEC-1-B cells and organoids which were subjected to immunofluorescence detection of A. YAP and B. phospho-YAP after VP treatment. YAP and phospho-YAP are conjugated with goat anti-mouse and goat anti-rabbit Alexa flour secondary antibodies respectively. (A) Upper panel bar=63x and lower panel bar = 20x. (B) Upper panel bar=63x and lower panel bar = 20x.

30254296 28404908
体内試験 Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (139.12 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 718.79
化学式

C41H42N4O8

CAS No. 129497-78-5
保管
in solvent
別名 CL 318952

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03067051 Recruiting Recurrent Prostate Cancer SpectraCure AB March 21 2017 Phase 1
NCT03067051 Recruiting Recurrent Prostate Cancer SpectraCure AB March 21 2017 Phase 1
NCT03033225 Recruiting Pancreatic Cancer Non-Resectable Mayo Clinic January 5 2017 Phase 2
NCT03033225 Recruiting Pancreatic Cancer Non-Resectable Mayo Clinic January 5 2017 Phase 2
NCT02939274 Recruiting Metastatic Breast Cancer Rogers Sciences Inc. October 2016 Phase 2
NCT02939274 Recruiting Metastatic Breast Cancer Rogers Sciences Inc. October 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VDAシグナル伝達経路

相関VDA製品

Tags: Verteporfin を買う | Verteporfin ic50 | Verteporfin 供給者 | Verteporfin を購入する | Verteporfin 費用 | Verteporfin 生産者 | オーダーVerteporfin | Verteporfin 化学構造 | Verteporfin 分子量 | Verteporfin 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID